Mills Katherine L, Teesson Maree, Ross Joanne, Darke Shane, Shanahan Marian
National Drug and Alcohol Research Centre of the University of New South Wales, Randwick, N.S.W. 2052, Australia.
Psychiatr Serv. 2005 Aug;56(8):940-5. doi: 10.1176/appi.ps.56.8.940.
This study examined the costs and outcomes of treatment for opiate dependence associated with posttraumatic stress disorder (PTSD).
Data were collected on the use of opiate treatment over a 12-month period for a cohort of 495 individuals, of whom 42 percent had PTSD. Total treatment costs were calculated as the sum of the time spent in each treatment modality multiplied by the appropriate unit cost. Outcome measures included occupational functioning, use of heroin and other drugs, and physical and mental health.
No significant difference was noted in the cost of treatment over the 12-month period for persons with and without PTSD (5,394+/-5,136 and 4,821+/-5,144 [Australian dollars], respectively). However, persons with PTSD had poorer treatment outcomes in terms of occupational functioning, overdose, and physical and mental health.
Although the same resources were invested in opiate treatment for persons with and without PTSD, PTSD continued to be associated with poorer functioning in a number of domains at 12-month follow-up. A well-designed intervention targeting both heroin dependence and PTSD may help to improve the outcomes of persons with PTSD.
本研究探讨了与创伤后应激障碍（PTSD）相关的阿片类药物依赖的治疗成本及治疗效果。
收集了495名个体在12个月期间使用阿片类药物治疗的数据，其中42%患有PTSD。总治疗成本计算为每种治疗方式所花费的时间乘以相应的单位成本。结果指标包括职业功能、海洛因及其他药物的使用情况以及身心健康状况。
在12个月的治疗期间，患有和未患有PTSD的患者在治疗成本上未发现显著差异（分别为5394±5136澳元和4821±5144澳元）。然而，患有PTSD的患者在职业功能、药物过量以及身心健康方面的治疗效果较差。
尽管对患有和未患有PTSD的患者在阿片类药物治疗上投入了相同的资源，但在12个月的随访中，PTSD在多个领域仍与较差的功能状况相关。针对海洛因依赖和PTSD设计的精心干预措施可能有助于改善患有PTSD患者的治疗效果。
